Monograph
J07AJ52 - Pertussis, Purified Antigen, Combinations with Toxoids |
Propably not porphyrinogenic |
PNP |
Side effects
Common adverse reactions of the vaccine that can be confused with an acute porphyric attack are nausea, vomiting, diarrhea and abdominal pain. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Based on the pharmacokinetics of the pertussis combination vaccine there are no conceivable porphyrinogenic effects.
Chemical description
Antigens from Bordetella Pertussis and diphtheria and tetanus toxoids.
Therapeutic characteristics
The pertussis combination vaccine is indicated for booster vaccination against diphtheria, tetanus and pertussis in individuals from age four years and older.
It is administered as a single dose by deep intramuscular injection
Metabolism and pharmacokinetics
The pertussis combination vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995 Sep;96(3 Pt 2):557-66.
Decker MD, Edwards KM, Steinhoff MC, et al. |
|
| * | Government bodies | |
| 2. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015)
|
|
| * | Summary of Product Characteristics | |
| 3. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Boostrix.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024